Investigational Drug Information for Triapine
✉ Email this page to a colleague
What is the development status for investigational drug Triapine?
Triapine is an investigational drug.
There have been 33 clinical trials for Triapine.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 15th 2016.
The most common disease conditions in clinical trials are Adenocarcinoma, Vaginal Neoplasms, and Uterine Cervical Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Vion Pharmaceuticals, and NRG Oncology.
There are three hundred and eighty-one US patents protecting this investigational drug and four international patents.
Summary for Triapine
| US Patents | 381 |
| International Patents | 4,228 |
| US Patent Applications | 885 |
| WIPO Patent Applications | 600 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 2 (2016-01-15) |
| Vendors | 59 |
Recent Clinical Trials for Triapine
| Title | Sponsor | Phase |
|---|---|---|
| Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors | National Cancer Institute (NCI) | Phase 2 |
| Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy | National Cancer Institute (NCI) | Early Phase 1 |
| Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors | National Cancer Institute (NCI) | Phase 1 |
Clinical Trial Summary for Triapine
Top disease conditions for Triapine
Top clinical trial sponsors for Triapine
US Patents for Triapine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Triapine | ⤷ Try a Trial | Methods and compositions for inhibition of Ras | ARAXES PHARMA LLC (San Diego, CA) | ⤷ Try a Trial |
| Triapine | ⤷ Try a Trial | Treatment of solid tumours | VIVOLUX AB (Uppsala, SE) | ⤷ Try a Trial |
| Triapine | ⤷ Try a Trial | Polynucleotides encoding immune modulating polypeptides | ModernaTX, Inc. (Cambridge, MA) | ⤷ Try a Trial |
| Triapine | ⤷ Try a Trial | Substituted imidazo[1,5-a]pyrazines as Btk inhibitors | Merck Sharp & Dohme Corp. (Rahway, NJ) | ⤷ Try a Trial |
| Triapine | ⤷ Try a Trial | Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid | MERCK & CIE (Schaffhausen, CH) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Triapine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Triapine | World Intellectual Property Organization (WIPO) | WO2016049568 | 2034-09-25 | ⤷ Try a Trial |
| Triapine | Australia | AU2012231814 | 2031-03-21 | ⤷ Try a Trial |
| Triapine | Brazil | BR112013024211 | 2031-03-21 | ⤷ Try a Trial |
| Triapine | Canada | CA2830081 | 2031-03-21 | ⤷ Try a Trial |
| Triapine | China | CN103547268 | 2031-03-21 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
